Lenalidomide, thalidomide similar when combined with melphalan and prednisone for multiple myelomaSeptember 18, 2015Lymphoma & Plasma Cell Disorders
The ‘financial toxicity’ of multiple myelomaSeptember 18, 2015Practice ManagementLymphoma & Plasma Cell Disorders
Excellent survival after ASCT for light-chain amyloidosisSeptember 16, 2015Lymphoma & Plasma Cell Disorders
Whole-exome sequencing reveals important mutations in myelomaSeptember 9, 2015Lymphoma & Plasma Cell Disorders
CTL019 induced a durable complete response in refractory MMSeptember 9, 2015Lymphoma & Plasma Cell Disorders
Obinutuzumab trends better than rituxumab in relapsed indolent lymphomaSeptember 3, 2015Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Imetelstat elicits response in myelofibrosis, thrombocythemiaSeptember 2, 2015Lymphoma & Plasma Cell Disorders
Daratumumab monotherapy impresses in hard-to-treat multiple myelomaAugust 31, 2015Lymphoma & Plasma Cell Disorders
Lenalidomide + rituximab combo effective in recurrent follicular lymphomaAugust 24, 2015Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Secondary CNS lymphoma regimen linked to 41% survival at 5 yearsAugust 23, 2015Lymphoma & Plasma Cell Disorders
Continuous therapy improved outcomes in multiple myelomaAugust 17, 2015Lymphoma & Plasma Cell Disorders
